Qun-Ying Yue, Uppsala Monitoring Centre (Sweden) Zhang Li, Dongfang Hospital, Beijing University of Chinese Medicine (China) Manal Younus, Iraqi Pharmacovigilance Center (Iraq) Marco Tuccori, University of Pisa, Chair of ISoP Italian Chapter (Italy) Mónica Tarapués, Universidad Central del Ecuador (Ecuador) Souad Skalli, Mohammed V University (Morocco) Ugo Moretti, University of Verona (Italy )Īntoine Pariente, University of Bordeaux (France)Įmanuel Raschi, University of Bologna (Italy) Roberto Leone, University of Verona (Italy) Ylenia Ingrasciotta, University of Verona (Italy) Mira Harrison-Woolrych, ISoP President (New Zealand) Linda Härmark, Pharmacovigilance Centre Lareb (The Netherlands) Paola Maria Cutroneo, University Hospital of Messina (Italy)Ĭarmen Ferrajolo, Italian Medicines Agency (Italy) Salvatore Crisafulli, University of Verona (Italy) Rebecca Chandler, Coalition for Epidemic Preparedness Innovations (Sweden) Helen Byomire Nagije, National Drug Authority (Uganda) Melissa Bernal, Colombian Pharmacovigilance Association (Colombia) Ghita Benabdallah, Centre Anti Poison et de Pharmacovigilance du Maroc (Morocco) Thamir Alshammari, King Saud University (Saudi Arabia)Įlena Arzenton, University of Verona (Italy) Mayada Alkhakany, Boehringer Ingelheim (Germany) Mónica Tarapués, Central University of Ecuador (Ecuador)Ĭhairs: Angela Caro Rojas, Pontificia Universidad Javeriana (Colombia) and Gianluca Trifirò, University of Verona (Italy)

''By becoming a member of ISoP, you will have the opportunity to share your knowledge and ideas and to contribute to improving pharmacovigilance activities worldwide.''ĭr Mira Harrison-Woolrych, President of the International Society of Pharmacovigilance The Society is open to anyone interested in learning about better ways for patients to receive and use medicines safely, including academics, epidemiologists, medicines regulators, clinical pharmacologists, pharmaceutical industry representatives, practising clinicians, pharmacists, and other healthcare professionals.įrom Argentina to Zimbabwe, in countries in Europe to Asia, across the Americas, and from Australia to Africa, we have members in all five continents. ISoP encourages and supports the use of all types of information and methodologies in providing optimal drug treatment for patients. This decision-analytically motivated threshold can then be used in ROC space to see what sensitivity and specificity relate to this cutoff.The International Society of Pharmacovigilance (ISoP) aims to develop its activities on a worldwide basis towards supporting safer use of medicines in clinical practice.

The classic decision-analytic formula is that the odds of the threshold is equal to this ratio, for example 1:1 implies a threshold of 50% 1:4 implies a threshold of 20%. The utility-based approach leads to a decision threshold that reflects the ratio of harms (overdiagnosis, FP classifications) to benefit (gain for those correctly diagnosed, TP classifications).

This makes sense since the likelihood ratio of such as prediction is 1: the prediction after using the prediction model is equal to the prior probability of the disease without using the model, and the likelihood ratio is the tangent of the ROC curve. The upper left point in ROC space corresponds to using the mean prevalence of disease as the threshold. Prediction models are useful to estimate individualized probabilities, and ROC analysis is frequently applied to quantify the quality of a prediction model. The decision threshold is in terms of a probability of the endpoint, say probability that disease is present in a diagnostic problem. I would like to bring up the link with the choice of the decision threshold for classification of patients as positive vs negative, with an action such as 'treat' connected to positive classification.

Xlstat s vector method